PALI Oppenheimer initiated coverage of Palisade Bio with an Outperform rating and $8 price target. The firm believes Palisade Bio offers inv

PALI Oppenheimer initiated coverage of Palisade Bio with an Outperform rating and $8 price target. The firm believes Palisade Bio offers investors an attractive way to participate in the large/growing inflammatory bowel disease space as the company's therapeutic development programs move toward their first Phase 2 readout next year. Oppenheimer thinks PALI-2108's appeal lies in its potential for biologic-like early symptom improvement paired with a once-daily oral profile better suited for long-term maintenance - a profile that could fill a critical gap in the evolving IBD drug landscape.